Skip to main content
Clinical Trials/NCT04538287
NCT04538287
Completed
Not Applicable

AtaCor Subcostal Temporary Extravascular Pacing III Study

AtaCor Medical, Inc.4 sites in 3 countries33 target enrollmentOctober 3, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Conduction Defect
Sponsor
AtaCor Medical, Inc.
Enrollment
33
Locations
4
Primary Endpoint
Performance - Pacing Impedance
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Third in-human study for the AtaCor Extravascular (EV) Temporary Pacing Lead System to collect initial safety and performance data for the latest AtaCor System.

The objective of the study is to generate safety and performance data of the latest AtaCor EV Temporary Pacing Lead System 1) to support the development a future pivotal study with an indication limited to a maximum of 7 days, and 2) to obtain early clinical data for future research related to longer-term use.

Detailed Description

Prior revisions of the study intended to evaluate multiple StealthTrac Leads (Models AC-1010, AC-1020, AC-2021 and AC-1030) to support the development of a future pivotal study. In the most recent revision of the study, an additional StealthTrac Lead (Model AC-1012) will be evaluated to support use in a larger pivotal study. This study is a feasibility study serving dual purposes: 1) to generate developmental clinical data in support of a subsequent pivotal clinical study and marketing application for temporary pacing (in patients that retain the lead for a maximum of 7 days); and 2) to obtain early data for future research related to longer-term use (in patients that retain the lead for a maximum of 14 days). Subjects undergoing a qualifying index procedure will have a Model AC-1012 StealthTrac Lead inserted, evaluated for a Maximum Lead Insertion Time prior to removal and a final post-removal follow-up 27-33 days after lead insertion. The following elements will change after the absence of AtaCor-related cardiac tamponade and no more than one (1) serious AtaCor-related pericardial effusion has been confirmed from the initial eight (8) experiences with the Model AC-1012 StealthTrac Lead, including insertion and removal procedures performed by multiple operators: * Maximum Lead Insertion Time will change from 7 to 14 Days * Follow-up will change from in-hospital follow-up only to allowing hospital discharge with the StealthTrac lead inserted, but capped and inactive after Day 2 provided in-person wound checks occur at least every 3 days * Echocardiography requirements will transition from 3 distinct days to procedure day and removal day only.

Registry
clinicaltrials.gov
Start Date
October 3, 2020
End Date
May 11, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • At least 18 years old
  • Indicated for closed-chest cardiac invasive procedure (e.g. transcatheter valve replacement, balloon valvuloplasty, permanent pacemaker implantation and pacing lead extractions/revisions)

Exclusion Criteria

  • NYHA IV functional class
  • Oxygen dependency
  • BMI ≥ 35 kg/m2
  • Circumstances that prevent data collection or follow-up (e.g., inability to perform a short walk with the Holter monitor)
  • Participation in any concurrent clinical study without prior written approval from the Sponsor
  • Inability to give an informed consent to participate in the Study
  • Known prior history for any of the following:
  • Median or partial sternotomy
  • Surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium
  • Significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)

Outcomes

Primary Outcomes

Performance - Pacing Impedance

Time Frame: Lead removal (up to 14 Days)

Summary statistics for pacing impedance for each StealthTrac Lead model from insertion through removal for each StealthTrac Lead model from insertion through removal

Safety - Freedom from Adverse Device Effects

Time Frame: Lead removal (up to 14 Days)

Freedom from Adverse Device Effects (ADE)

Performance - Sensed R-wave Amplitude

Time Frame: Lead removal (up to 14 Days)

Summary statistics for sensed R-wave amplitude for each StealthTrac Lead model from insertion through removal

Performance - Pacing Capture Threshold

Time Frame: Lead removal (up to 14 Days)

Summary statistics for pacing capture threshold for each StealthTrac Lead model from insertion through removal

Study Sites (4)

Loading locations...

Similar Trials